ReviewKorean circulation journal2025
Management of Coronary Artery Disease in Patients With Severe Aortic Stenosis.
Review in Korean circulation journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How to Individualize Coronary Assessment and Revascularization in Severe AS Patients Undergoing TAVI in the Era of Lifetime Management?Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coexistence of severe aortic stenosis (AS) and coronary artery disease (CAD) presents complex diagnostic and therapeutic challenges, particularly as transcatheter aortic valve replacement (TAVR) expands to younger, lower-risk populations. CAD prevalence in AS patients ranges from 27.7% in low-risk cohorts to 74.9% in high-risk populations, synergistically worsening ventricular function and prognosis. Diagnostic evaluation remains challenging due to overlapping symptomatology and altered coronary physiology in severe AS. While invasive coronary angiography remains the gold standard, coronary computed tomography (CT) angiography with CT-derived fractional flow reserve (FFR) shows promise as a non-invasive alternative. Standard FFR thresholds may not be reliable in AS patients, with emerging evidence suggesting AS-specific cutoffs may be needed. Treatment strategies must balance the complexity of CAD with patient risk profiles. Current guidelines recommend bypass surgery with surgical aortic valve replacement for complex multivessel disease, while percutaneous coronary intervention (PCI) with TAVR is preferred for less complex lesions or high-risk patients. The optimal timing of PCI relative to TAVR remains debated, with recent data favoring a "TAVR-first" approach for non-critical lesions. As TAVR extends to younger patients, lifetime management considerations become paramount, including valve durability, future coronary access, and planning for potential re-interventions. Commissural alignment techniques during TAVR are crucial for preserving future coronary access. A multidisciplinary Heart Team approach with robust shared decision-making is essential for optimizing individualized care in this evolving field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.